Peripherally administered amylin inhibits stress-like behaviors and enhances cognitive performance
Authors:
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Physiology & Behavior
- Vol. 244, 113668
Abstract
No abstract availableKeywords
Funding Information
- Amylin Pharmaceuticals
- USDA ARS (2032–51,530–022–00-D)
- U.S. Department of Agriculture
This publication has 49 references indexed in Scilit:
- Accelerated Progression From Mild Cognitive Impairment to Dementia in People With DiabetesDiabetes, 2010
- Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysisDiabetologia, 2010
- Allostatic load is associated with chronic conditions in the Boston Puerto Rican Health StudySocial Science & Medicine, 2010
- Psychosocial Stress at Work Doubles the Risk of Type 2 Diabetes in Middle-Aged WomenDiabetes Care, 2009
- Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research studyAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Prospective Effect of Job Strain on General and Central Obesity in the Whitehall II StudyAmerican Journal of Epidemiology, 2007
- Pramlintide in the treatment of diabetesInternational Journal Of Clinical Practice, 2006
- Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing studyDiabetes/Metabolism Research and Reviews, 2004
- The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned ratsInternational Journal of Obesity, 2001
- Carbohydrate CravingDrugs, 1990